--- title: "U.S. stock market midday update: Scinai drops 21.48% with trading volume surging, financing news triggers market volatility!" type: "News" locale: "en" url: "https://longbridge.com/en/news/284239910.md" description: "Scinai Immunotherapeutics fell 21.48%; AbbVie rose 0.79%, with a transaction volume of USD 463 million; Oruka Therapeutics rose 20.25%, with a transaction volume of USD 351 million; Sagimet Biosciences rose 46.12%, with a transaction volume of USD 299 million; Amgen fell 0.17%, with a market capitalization of USD 185.6 billion" datetime: "2026-04-27T15:03:33.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284239910.md) - [en](https://longbridge.com/en/news/284239910.md) - [zh-HK](https://longbridge.com/zh-HK/news/284239910.md) --- # U.S. stock market midday update: Scinai drops 21.48% with trading volume surging, financing news triggers market volatility! **U.S. Stock Market Midday Update** Scinai fell 21.48%, with increased trading volume. Based on recent key news: 1. On April 25, Scinai Immunotherapeutics announced a securities purchase agreement, leading to stock price fluctuations. Institutional investors agreed to exercise warrants for 229,310 shares at $0.48 per share and received an additional 458,621 warrants with an exercise price of $0.55. This news triggered active trading in the market, with a trading volume exceeding 33 million shares, far above the three-month average daily trading volume of 101,000 shares. Source: Benzinga 2. On April 24, Scinai Immunotherapeutics announced a $2.61 million private placement financing. This financing includes 5,208,333 ADS at a price of $0.48 per share, along with warrants. This news drove the stock price up. Source: PR Newswire 3. On April 24, Scinai Immunotherapeutics' stock price rose 92.11% to $0.87 following the financing announcement. This news attracted market attention, causing significant stock price fluctuations. Source: Benzinga The biotechnology industry has seen frequent financing activities recently, intensifying market volatility. **Stocks with High Trading Volume in the Industry** AbbVie rose 0.79%, with increased trading volume. Based on recent key news: 1. On April 27, AbbVie submitted a new dosage application for SKYRIZI to the FDA, supporting its use in the treatment of Crohn's disease. This move may enhance market confidence in its product line, driving the stock price up. Source: AbbVie Company Announcement 2. On April 24, the FDA rejected AbbVie's wrinkle treatment drug due to manufacturing issues. Although safety or efficacy was not involved, it may affect market confidence in its R&D capabilities. Source: Reuters 3. On April 24, AbbVie announced a $195 million investment to establish a new manufacturing facility in North Carolina, aimed at enhancing supply chain resilience and supporting long-term growth. This move may elevate investor expectations for its future development. Source: Pharmaceutical Executive Daily The pharmaceutical industry is facing intensified competition and a tightening regulatory environment. Oruka Therapeutics rose 20.25%. Based on recent key news: 1. On April 27, Oruka Therapeutics announced that its experimental injectable psoriasis treatment achieved its primary endpoint in a mid-stage clinical trial, with 63.5% of patients achieving complete skin clearance within 16 weeks, driving the stock price up. Source: Reuters 2. On April 27, analysts generally rated Oruka Therapeutics as a buy, with an average target price of $78.90, further enhancing market confidence. Source: Benzinga On April 27, Oruka plans to share more long-term data in the second half of 2026, including 28 weeks of efficacy and 52 weeks of follow-up, demonstrating confidence in future development. Source: GlobeNewswire The biotechnology industry has been active recently, with significant capital inflows. Sagimet Biosciences rose 46.12%. Based on recent key news: 1. On April 27, Sagimet Biosciences announced an underwritten offering of 29,166,700 shares of Class A common stock at a price of $6 per share, with total expected proceeds of $175 million. This move drove the stock price up, with a significant increase in trading volume. Source: GlobeNewswire 2. On April 27, the company plans to use the net proceeds and existing capital to fund the Phase 3 trial of denifanstat and advance the development of TVB-3567 and topical FASN inhibitors. This news has enhanced market confidence in the company's future development. Source: GlobeNewswire 3. On April 27, Spark's AI analyst holds a neutral stance on SGMT stock, noting that despite weak financial performance, technical momentum and clinical progress are positive. This analysis provides investors with a more comprehensive perspective. Source: TipRanks The biopharmaceutical industry has seen significant capital inflows recently, with risks to watch. **Stocks ranked among the top in industry market capitalization** Amgen fell 0.17%, with increased trading volume. Based on recent key news: 1. On April 25, Amgen announced it will release its Q1 2026 financial report on April 30 and hold a conference call. This news has attracted market attention, with investors taking a wait-and-see approach to the upcoming financial report, leading to a slight decline in stock price. 2. On April 26, market analysis showed that although Amgen maintains a "hold" rating among analysts, some analysts believe that five other stocks have more investment value. This rating information may have affected investor confidence, putting pressure on the stock price. 3. On April 25, as a component of the Dow Jones Industrial Average and the Nasdaq 100 Index, Amgen's market performance has attracted widespread attention. Investors are cautious about its performance in these indices, affecting stock price fluctuations. The biopharmaceutical industry has shown stable performance recently, with a focus on financial reports ### Related Stocks - [SCNI.US](https://longbridge.com/en/quote/SCNI.US.md) ## Related News & Research - [OSE narrows pipeline focus amid Boehringer MASH collaboration retreat](https://longbridge.com/en/news/277660319.md) - [Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026 | SCNI Stock News](https://longbridge.com/en/news/279779919.md) - [Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration | SCNI Stock News](https://longbridge.com/en/news/281359166.md)